OPKO Health Q4 2022 revenue drops to $185.4M; net loss $85.2M

OPKO HEALTH, INC.

2022-FY EPS reported -$0.46 revenue$1,004,196,000

Consolidated revenue $185.4M vs $401.3M YoY; net loss $85.2M ($0.11/share) includes $49.1M non-cash charge on GeneDx investment.
Diagnostics revenue $139.4M (down from $362.8M) due to COVID-19 testing decline; BioReference processed 0.1M PCR tests vs 2.7M.
Pharmaceuticals revenue $37.9M (up from $35.3M) driven by RAYALDEE ($9.1M) and IP transfer ($8.1M); NGENLA sales underway in 15 countries.
Operating loss $55.3M vs $63.1M; cash $153.2M as of Dec 31, 2022.
BioReference implementing cost-cutting initiatives to return to profitability after COVID-19 testing decline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.